Group 1 - The company is proposing a stock option incentive plan for 2025 to attract and retain talent, aligning the interests of shareholders, the company, and core team members [5][6][8] - The stock option incentive plan has been approved by the company's board and supervisory committee and is now submitted for shareholder approval [6][8] - The company will conduct the shareholder meeting on July 14, 2025, with both on-site and online voting options available [5][7] Group 2 - The company plans to change its name from "Jiangsu Aidea Pharmaceutical Co., Ltd." to "Jiangsu Aidea Pharmaceutical Group Co., Ltd." to enhance group management and resource utilization [12][13] - The name change aligns with the company's strategic development needs and will not adversely affect its operations or shareholder interests [13][14] - The company will also revise its articles of association to reflect the name change and will seek necessary approvals for the changes [14][22] Group 3 - The company intends to adjust its fundraising investment projects, specifically changing the focus from "Ustectidine New Indication Research Project" to "Integrase Inhibitor Drug Research and Clinical Study Project" [16][19] - The total amount of funds to be redirected is approximately 84.37 million yuan, which will be fully allocated to the new project [15][19] - The integrase inhibitor project aims to develop a new generation of anti-HIV drugs and has shown promising results in initial clinical trials [20][21] Group 4 - The company is proposing the appointment of a new independent director candidate, Hu Wenyuan, following the resignation of the previous independent director [11][12] - The nomination has been approved by the board and is now subject to shareholder approval [11][12] - The company is also seeking to fill a vacancy in the supervisory board due to the resignation of a non-employee representative supervisor [22][23]

Core Viewpoint - The company has approved the initial list of incentive recipients for the 2025 stock option incentive plan, ensuring compliance with relevant regulations and internal governance [1][2][3] Disclosure Situation - The company publicly disclosed the names and positions of the proposed incentive recipients internally from June 27, 2025, to July 7, 2025, for a minimum of 10 days, allowing employees to provide feedback [1] Review Method - The supervisory board verified the proposed recipients' identities, employment contracts, and positions within the company and its subsidiaries [2] Supervisory Board Review Opinion - The supervisory board confirmed that all proposed recipients meet the qualifications set forth by relevant laws and regulations, including not being disqualified by the securities exchange or regulatory authorities in the past 12 months [2][3]

证券代码：688488 证券简称：艾迪药业 公告编号：2025-035 江苏艾迪药业股份有限公司 监事会关于 2025 年股票期权激励计划 公司于 2025 年 6 月 27 日至 2025 年 7 月 7 日，通过办公 OA 系统在公司内 部对本次拟激励对象的姓名和职务进行了公示，公示时间不少于 10 天，公司员 工可在公示期限内向监事会提出反馈意见。 至公示期满，公司监事会未收到任何组织或个人对本次拟激励对象的异议。 二、审核方式 公司监事会对拟激励对象的核查方式：公司监事会核查了本激励计划拟首次 授予激励对象的名单、身份证件、拟首次授予激励对象与公司（含子公司）签订 的劳动合同/劳务合同、首次授予激励对象在公司（含子公司）担任的职务及其 任职文件等。 三、监事会核查意见 监事会根据《管理办法》的规定，对本激励计划首次授予激励对象名单进行 了核查，并发表核查意见如下： 首次授予激励对象名单的审核意见及公示情况说明 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏艾迪药业股份有限公司（以下简称"公司"）于 2025 ...

江苏艾迪药业股份有限公司 董事会薪酬与考核委员会 关于 2025 年股票期权激励计划 首次授予激励对象名单的审核意见及公示情况说明 证券代码：688488 证券简称：艾迪药业 公告编号：2025-036 2、激励对象不存在《管理办法》规定的不得成为激励对象的情形： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏艾迪药业股份有限公司（以下简称"公司"）于 2025 年 6 月 27 日召开 第三届董事会第四次会议、第三届监事会第四次会议，审议通过了《关于公司＜ 2025 年股票期权激励计划（草案）＞及其摘要的议案》等相关议案。 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）《上海证券 交易所科创板股票上市规则》《科创板上市公司自律监管指南第 4 号——股权激 励信息披露》的相关规定，对公司《2025 年股票期权激励计划（草案）》（以下 简称"《激励计划（草案）》"、"本激励计划"）中拟首次授予激励对象的姓名和职 务在公司内部进行了公示。公司董事会薪酬与考核委员会结合公示情况对本激励 计划拟首次授予激励对象 ...

江苏艾迪药业股份有限公司 2025 年第二次临时股东会会议资料 二○二五年七月 江苏艾迪药业股份有限公司 2025 年第二次临时股东会会议资料 江苏艾迪药业股份有限公司 2025 年第二次临时股东会会议资料目录 | 2025年第二次临时股东会会议须知 | 3 | | --- | --- | | 2025年第二次临时股东会会议议程 | 5 | | 2025年第二次临时股东会会议议案 | 6 | | 议案1 关于公司《2025年股票期权激励计划（草案）》及其摘要的议案 | 6 | | 议案2 关于公司《2025年股票期权激励计划实施考核管理办法》的议案 | 7 | | 议案3 关于提请股东会授权董事会办理公司2025年股票期权激励计划相关事宜的 | | | 议案 8 | | | 议案4 关于聘任独立董事的议案 | 10 | | 议案5 关于变更公司名称及修改《公司章程》的议案 | 11 | | 议案6 关于变更部分募集资金投资项目及金额调整的议案 | 14 | | 议案7 关于补选第三届监事会非职工代表监事的议案 | 18 | 2 四、为保证会场秩序，进入会场后，请关闭手机或调至振动状态。谢绝个人 录音、拍照及录 ...

Core Viewpoint - The National Medical Products Administration (NMPA) has released the "Guidelines for Clinical Resistance Research and Data Submission for Anti-HIV Drugs," establishing a standardized benchmark for HIV drug development in China [2][3]. Group 1: Regulatory Changes - The new guidelines aim to address the urgent issue of HIV drug resistance, which poses significant challenges to treatment efficacy and public health [4]. - The guidelines introduce stricter requirements for drug development, raising the bar for the industry and encouraging companies to develop safer and more effective new drugs [4][5]. Group 2: Company Involvement - Aidi Pharmaceutical, a leading company in the anti-HIV field, actively participated in the formulation of these guidelines, sharing its extensive experience in resistance research [5][6]. - The company has been recognized for its commitment to tackling HIV challenges and has contributed valuable insights during the guideline consultation process [5][6]. Group 3: Research and Development - Aidi Pharmaceutical's existing drugs, such as Ainovelin and Ainomir, have shown excellent clinical performance with low cross-resistance to previous non-nucleoside drugs, providing effective treatment options for patients [7]. - The company is also developing a new integrase inhibitor, ACC017, which has shown promising results in early clinical trials, indicating good safety and efficacy profiles [8]. Group 4: Future Directions - Aidi Pharmaceutical plans to continue increasing its R&D investments and enhancing its innovation capabilities in response to the new guidelines, aiming to develop more high-quality anti-HIV drugs [9]. - The company emphasizes the importance of resistance research in drug development and aims to contribute significantly to China's HIV prevention and treatment efforts [9].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has launched a stock option incentive plan aimed at boosting the sales of its HIV drugs, with specific performance targets set for different groups of employees. The plan is designed to be comprehensive and operationally feasible [4] - The sales of HIV drugs have shown significant growth, with Q1 2025 sales reaching 62 million yuan, a year-on-year increase of 75.64%, marking a historical high for the company [5] - The company is expected to achieve a turnaround in profitability, with projected net profits for 2025-2027 revised to -0.02 billion, 0.44 billion, and 0.88 billion yuan respectively [4] Financial Summary and Valuation Indicators - Revenue is projected to grow from 411.4 million yuan in 2023 to 1,237 million yuan in 2027, with a year-on-year growth rate of 76.4% in 2025 [7] - The gross margin is expected to improve significantly, reaching 72.9% in 2025 and 81.2% by 2027 [7] - The company's price-to-sales (P/S) ratio is projected to decrease from 15.1 in 2023 to 5.0 in 2027, indicating an improving valuation as revenues grow [7]

Meeting Overview - The third meeting of the Supervisory Board of Jiangsu Aidi Pharmaceutical Co., Ltd. was held on June 27, 2025, with all three supervisors present, confirming the legality and validity of the meeting [1]. Resolutions Passed - The Supervisory Board approved the proposal to cancel part of the unvested restricted stock, stating that it complies with relevant laws and regulations, and does not harm shareholders' interests [1][2]. - The Supervisory Board approved the draft of the 2025 Stock Option Incentive Plan, which aligns with legal requirements and is expected to benefit the company's sustainable development [2][3]. - The Supervisory Board approved the implementation assessment management measures for the 2025 Stock Option Incentive Plan, ensuring smooth execution and alignment with the company's governance structure [3][4]. - The Supervisory Board verified the list of initial incentive objects for the 2025 Stock Option Incentive Plan, confirming their qualifications under relevant laws and regulations [4][5]. - The Supervisory Board approved changes to certain fundraising investment projects and amount adjustments, aimed at enhancing operational stability and profitability [5][6]. - The Supervisory Board agreed to nominate Tang Jieqing as a candidate for a non-employee representative supervisor, pending shareholder approval [6][7]. - The Supervisory Board elected current employee representative supervisor Pang Qiuchen as the chairman of the Supervisory Board, effective immediately [7].

Core Viewpoint - Jiangsu Aidi Pharmaceutical Co., Ltd. is adjusting its fundraising investment projects to enhance the efficiency of fund usage and expedite the development of advantageous projects, specifically by reallocating funds from the "Ustectidine New Indication Research Project" to the "Integrase Inhibitor Drug Research and Clinical Study Project" [4][8][14] Fundraising Investment Project Overview - As of June 20, 2025, the raw material drug production research and supporting facilities project has been completed, while other fundraising projects are ongoing [2] - The total amount of committed investment for the projects is 542.8 million yuan, with 396.6 million yuan invested by June 20, 2025 [3] Changes and Amount Adjustments - The company plans to change the name of the project "Ustectidine New Indication Research Project" to "Integrase Inhibitor Drug Research and Clinical Study Project" and adjust the investment amounts accordingly [4][5] - The remaining funds of 84.3699 million yuan from the original project will be fully allocated to the new project to meet its funding needs [6][9] Reasons for Changes - The original project faced delays due to stricter regulatory requirements and the need for further evaluations, prompting the company to reallocate funds to a project with more immediate needs [7][8] - The "Integrase Inhibitor Drug Research and Clinical Study Project" is crucial for the company's pipeline, aiming to develop a new generation of integrase inhibitors for HIV treatment [9][10] Impact of Changes - The adjustments are expected to improve the efficiency of fund usage and support the company's long-term development strategy without adversely affecting normal operations [12][14] - The project aims to enhance the effectiveness and safety of HIV treatments, aligning with national policy goals and expanding the company's product offerings [10][12] Approval Process - The board of directors and the supervisory board have approved the changes, which will be submitted for shareholder approval [13][14]

证券代码：688488 证券简称：艾迪药业 公告编号：2025-032 江苏艾迪药业股份有限公司 关于开立募集资金临时补流专项账户并签署募集资 金临时补流专户存储三方监管协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏艾迪药业股份有限公司（以下简称"艾迪药业"或"公司"）于 2025 年 6 月 27 日召开了第三届董事会第四次会议，审议通过了《关于开立募集资金 临时补流专项账户并签署募集资金临时补流专户存储三方监管协议的议案》，现 将有关情况公告如下： 一、 募集资金基本情况 经中国证券监督管理委员会出具《关于同意江苏艾迪药业股份有限公司首次 公开发行股票注册的批复》 （证监许可〔2020〕1185 号）核准，公司向社会公开 发行人民币普通股 6,000 万股，发行价为每股人民币 13.99 元，募集资金总额为 人民币 839,400,000.00 元，扣除承销费用和保荐费用合计含税金额 61,758,000.00 元，实际募集资金到账 777,642,000.00 元。本次股票发行累计发生发行费用含税 ...